SAMSUNG BIOEPIS UK LIMITED

Active
Company number 08840722Private limited companyIncorporated 2014

Key figures

£1,594,076+233.5%
Net assets 2025
+41.8%
Average annual growth 2020–2025
0500 k1 m1.5 m2 m202020212022202320242025

† SAMSUNG BIOEPIS UK LIMITED filed these accounts on paper, so Companies House publishes them only as a scanned image. The figures for the years marked † were read automatically from the scan and kept only where the statements add up (for example net assets equal total equity), but a reading error is still possible — check the original accounts at Companies House.

Like most small UK companies, SAMSUNG BIOEPIS UK LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2025

Sector comparison

SIC 82990

Where the company stands among the 160,475 active companies whose first SIC code is 82990 (Other business support service activities n.e.c.).

Net assets£1,594,076
Higher than 93% · median £13,183
Total assets£2,863,402
Higher than 92% · median £59,755
Cash£1,057,447
Higher than 93% · median £26,638
Company age12.9 years
Older than 60% · median 10.2 years

Positions are approximate. Figures come from each company's latest accounts; money and employee figures are compared only with companies that filed accounts in pounds for a period ending in the last two and a half years and are not dormant, so those groups are smaller than 160,475. The line on each bar marks the median.

Summary: SAMSUNG BIOEPIS UK LIMITED

What kind of company is it?

SAMSUNG BIOEPIS UK LIMITED is a private limited company registered with Companies House under company number 08840722. It was incorporated on 10 Jan 2014. Its status is active. The registered office is in Brentford (TW8). Its nature of business (SIC 2007) is other business support service activities n.e.c. (82990).

How is the company doing financially?

The latest accounts in the database are for 2025 (period ending 31 Dec 2025); the company files small company accounts. Net assets were £1,594,076, up 233.5% on the previous year. Cash at bank and in hand was £1,057,447. Total assets were £2,863,402 and total liabilities £1,195,686. Figures are available for 6 financial years (2020–2025).

How does it compare with similar companies?

Compared with 160,475 active companies whose first SIC code is 82990: By net assets it ranks higher than 93% of them (median £13,183). By total assets it ranks higher than 92% of them (median £59,755). By cash it ranks higher than 93% of them (median £26,638). It is older than 60% of them (median age 10.2 years).

Does it supply the public sector?

The company is named as a supplier in 4 public contract award notices from NHS England since 2024. 2 of the awards are shared with other suppliers, typically framework agreements.

Who runs and controls the company?

The company has 1 current director. One person with significant control is registered.

When are its next filings due?

The next accounts are due by 30 Sep 2027. The next confirmation statement is due by 28 Sep 2027.

Filed accounts2020–2025
20212022202320242025 †
Cash at bank and in hand598,602357,745360,160623,0421,057,447
Total assets849,649520,675606,6041,371,6722,863,402
Total liabilities527,583174,821——1,195,686
Net assets / total equity393,547395,341413,852477,9531,594,076
Average number of employees1111—

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Public contracts

4 contracts

SAMSUNG BIOEPIS UK LIMITED is named as a supplier in 4 public contract award notices from NHS England since 2024. 2 awards are shared with other suppliers.

Contracts per year
Contracts
  1. NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026‡NHS England · shared by 25 suppliers, up to £1,627,727,168 in total · 2 lots · runs until Aug 2028
  2. NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025‡NHS England · shared by 21 suppliers, up to £986,282,758 in total · runs until Aug 2027
  3. NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025‡NHS England · £2 · 2 lots
  4. NHS National Framework for Natalizumab-February 2024‡NHS England · £1

From contract award notices on Contracts Finder (since 2016) and Find a Tender (since 2021), published by the Cabinet Office under the Open Government Licence v3.0. Values are as published by the buyer and usually cover the whole contract term; the total leaves out awards shared between several suppliers, where the published figure is a ceiling for all of them, placeholder values and single figures of £1 billion or more. Notices marked ‡ do not state a company number and were linked by an exact match on the registered name. Contracts below the publication thresholds and those of devolved buyers that publish elsewhere are not included.

History

19 events
  1. Financial year 2025 endedAccounts: net assets £1.6m
  2. Financial year 2024 endedAccounts: net assets £478k, 1 employee
  3. Financial year 2023 endedAccounts: net assets £413.9k, 1 employee
  4. Sung Soo JUN resignedDirector
  5. Mr Ki Hyun Lee registered as a person with significant control
  6. Mr Sung Soo Jun ceased to be a person with significant control
  7. Ki Hyun LEE appointedDirector
  8. Financial year 2022 endedAccounts: net assets £395.3k, 1 employee
Earlier events (11)
  1. Financial year 2021 endedAccounts: net assets £393.5k, 1 employee
  2. Financial year 2020 endedAccounts: net assets £277.8k, 1 employee
  3. Sung Soo JUN appointedDirector
  4. Mr Sung Soo Jun registered as a person with significant control
  5. Sung Won PARK resignedDirector
  6. Mr Sung Won Park ceased to be a person with significant control
  7. Chulbo YANG resignedDirector
  8. Sung Won PARK appointedDirector
  9. Mr Sung Won Park registered as a person with significant control
  10. Chulbo YANG appointedDirector
  11. Company incorporatedPrivate limited company

Dates as recorded at Companies House: incorporation, name changes, officer appointments and resignations, current and former persons with significant control, and the end of each financial year with figures in the database.